| CKD | Chronic kidney disease |
| GFR | Glomerular filtration rate |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| RAS | Renin–angiotensin system |
| AVP | Arginine vasopressin |
| ESRD | End-stage renal disease |
| KRT | Kidney replacement therapy |
| PA | Physical activity |
| BP | Blood pressure |
| T2DM | Type 2 diabetes mellitus |
| IR | Insulin resistance |
| e-GFR | Estimated glomerular filtration rate |
| CVD | Cardiovascular disease |
| CNS | Central nervous system |
| KD | Ketogenic diets |
| PKD | Polycystic kidney disease if Intermittent fasting |
| PBD | Plant-based diets |
| MRAs | Mineralocorticoid receptor antagonist |
| NT-proBNP | N-terminal pro B-type natriuretic peptide |
| FIDELIO-DKD | Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease |
| FIGARO-DKD | Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease |
| MR | Mineralocorticoid receptor |
| UACR | Urine albumin-to-creatinine ratio |
| ASCVD | Atherosclerotic cardiovascular disease |
| CV | Cardiovascular |
| FDA | Food and Drug Administration |
| IL-1β | Interleukin 1β |
| NLRP3 | (NOD)-like receptor protein 3 |
| FMF | Familial Mediterranean fever |
| sJIA | Systemic juvenile idiopathic arthritis |
| PDE | Phosphodiesterase |
| cAMP | Cyclic adenosine monophosphate |
| PKA | Protein kinase A |
| hs-CRP | High-sensitivity C-reactive protein |
| TNF-α | Tumor necrosis factor α |
| PTF | Pentoxifylline |
| KDIGO | Kidney Disease: Improving Global Outcomes |
| PD | Peritoneal dialysis |
| HD | Hemodialysis |
| HDF | Hemodiafiltration |
| AFB | Acetate-free biofiltration |
| HF | Hemofiltration |
| HF | Heart failure |
| HIV | Human immunodeficiency virus |
| IDH | Intradialytic hypotension |
| SCD | Sudden cardiac death |
| OKT | Open kidney transplantation |
| RAKT | Robot-assisted kidney transplantation |
| TCMR | T-cell mediated rejection |
| ABMR | Antibody-mediated rejection |
| CKTR | Chronic kidney transplant rejection |
| IVIG | Intravenous immunoglobulins |
| PREDIAN | Pentoxifylline for Renoprotection in Diabetic Nephropathy |
| LEADER | Liraglutide Effect and Action in Diabetes |
| ARNI | Angiotensin receptor-neprilysin inhibitor |
| LVEF | Left ventricle ejection fraction |
| ACEI | Angiotensin-converting enzyme inhibitor |
| ARB | Angiotensin II receptor blocker |
| NICE | National Institute for Health and Care Excellence |